Page 151 - 2021_06-Haematologica-web

Antibody-mediated procoagulant platelets in VITT
MB, AB, HB, FD, AV, HH, NH, KK, CL, BL, JM, MM, SN, CS, BP, UJS, MW and GCP were responsible for the treatment of patients and collected and analyzed the clinical data; TB, GU, KA and FF reviewed medical reports; KA, GU, JAM, AS and LP per- formed the experiments; WAW and DV analyzed the radiological images; HB, VW, FF, and PM analyzed the autopsy findings and performed tissue studies; HJ produced Spike protein; KA, LP, AS, GU, NS, FF and TB analyzed the data, interpreted the results and wrote the manuscript. All authors read and approved the manuscript.
Acknowledgments
We thank our technicians Karoline Weich, Simone Weit,
Franziska Lyshy, Marco Mikus and Flavianna Rigoni for their excellent technical support. We also thank Harald Klüter and Martin Holderried for vaccines.
Funding
This work was supported by grants from the German Research Foundation and from the Herzstiftung to TB (BA5158/4 and TSG-Study), by special funds from the state of Baden-Württemberg for autopsy-based COVID-19 research and the DEFEAT PANDEMIcs network funded by the BMBF to PM and FF. JAM is supported by a grant from the German Research Foundation.
References
1. Grasselli G, Greco M, Zanella A, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med. 2020;180(10):1345-1355.
2. Castells MC, Phillips EJ. Maintaining safety with SARS-CoV-2 vaccines. N Engl J Med. 2021;384(7):643-649.
3. Althaus K, Marini I, Zlamal J, et al. Antibody-induced procoagulant platelets in severe COVID-19 infection. Blood. 2021; 137(8):1061-1071.
4. Wolf ME, Luz B, Niehaus L, Bhogal P, Bazner H, Henkes H. Thrombocytopenia and intracranial venous sinus thrombosis after "COVID-19 vaccine AstraZeneca"
Exposure. J Clin Med. 2021;10(8):1599.
5. Becker M, Strengert M, Junker D, et al. Exploring beyond clinical routine SARS- CoV-2 serology using MultiCoV-Ab to eval- uate endemic coronavirus cross-reactivity.
Nat Commun. 2021;12(1):1152.
6. Greinacher A, Michels I, Kiefel V, Mueller-
Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocy- topenia. Thromb Haemost. 1991;66(6):734- 736.
7. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092-2101.
8. Othman M, Labelle A, Mazzetti I, Elbatarny HS, Lillicrap D. Adenovirus-induced throm-
bocytopenia: the role of von Willebrand fac- tor and P-selectin in mediating accelerated platelet clearance. Blood. 2007;109(7):2832- 2839.
9. Schultz NH, Sorvoll IH, Michelsen AE, et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021;384(22):2124-2130.
10. Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018;13(2): 300-317.
11. Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res. 2001;88 (2):245-250.
haematologica | 2021; 106(8)
2179